1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,394 | 0,474 | 07:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ABBISKO-B (02256): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| Fr | ABBISKO-B (02256): (1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) CHANGE IN COMPOSITION OF AUDIT COMMITTEE, REMUNERATION COMMITTEE AND NOMINATION ... | 1 | HKEx | ||
| 17.02. | ABBISKO-B (02256): DATE OF BOARD MEETING | 1 | HKEx | ||
| 20.01. | BRIEF: Abbisko moves into the black in 2024 | 1 | Bamboo Works | ||
| 20.01. | ABBISKO-B (02256): POSITIVE PROFIT ALERT | 1 | HKEx | ||
| 20.12.24 | ABBISKO-B (02256): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 20.12.24 | ABBISKO-B (02256): RESIGNATION OF NON-EXECUTIVE DIRECTOR AND MATTERS RELATING TO RULE 13.92 OF THE LISTING RULES | 1 | HKEx | ||
| 16.12.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CDE APPROVAL TO INITIATE A REGISTRATIONAL CLINICAL STUDY OF IRPAGRATINIB (ABSK011) IN PATIENTS WITH HCC | 1 | HKEx | ||
| 11.12.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL STUDY OF ABSK043, AN ORAL PD-L1 SMALL-MOLECULE INHIBITOR, IN COMBINATION ... | 2 | HKEx | ||
| 09.12.24 | 2024 ASH Oral Presentation: Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting | 89 | PR Newswire | SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients... ► Artikel lesen | |
| 06.12.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ESMO ASIA 2024: ORAL PRESENTATION BY ABBISKO THERAPEUTICS ON UPDATED RESULTS FROM A PHASE I STUDY OF ABSK043, ... | 1 | HKEx | ||
| 03.12.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - U.S. FDA IND CLEARANCE FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR | 1 | HKEx | ||
| 22.11.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FIRST-PATIENT DOSED IN GASTRIC CANCER IN PHASE II CLINICAL STUDY EVALUATING ABSK043, AN ORAL PD-L1 INHIBITOR, ... | 2 | HKEx | ||
| 14.11.24 | Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type | 27 | PMLiVE | ||
| 13.11.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED RESULTS ON MODEL-INFORMED DOSE SELECTION FOR PIMICOTINIB AT ACOP 2024 | 1 | HKEx | ||
| 12.11.24 | Abbisko: Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial | 196 | PR Newswire | - The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant... ► Artikel lesen | |
| 12.11.24 | ABBISKO-B (02256): INSIDE INFORMATION - POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 MANEUVER STUDY OF PIMICOTINIB IN TGCT PATIENTS AND UPDATED RESULTS ... | 1 | HKEx | ||
| 08.11.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT PRELIMINARY PHASE 2 STUDY RESULTS OF PIMICOTINIB FOR THE TREATMENT OF CGVHD ... | 2 | HKEx | ||
| 23.10.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED PRECLINICAL RESEARCH RESULTS OF ITS PRMT5*MTA AND ORAL KRASG12D PROGRAMS AT ... | - | HKEx | ||
| 30.09.24 | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL | - | HKEx |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 56,17 | 0,00 % | Wieder zugeschlagen: Cathie Wood setzt auf Tempus AI - So will sie vom KI-Boom profitieren! | © Foto: ARK Invest/ Reed YoungNach einem Kursrutsch greift Cathie Wood massiv zu Tempus AI und setzt auf eine starke Erholung - die Aktie legt bereits 4 Prozent zu.Die bekannte Investorin Cathie Wood... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 57,75 | 0,00 % | Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts | ||
| RECURSION PHARMACEUTICALS | 7,510 | 0,00 % | Recursion Pharmaceuticals: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results | Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous... ► Artikel lesen | |
| QIAGEN | 36,625 | -0,56 % | Qiagen NV-Aktie kann Vortagsniveau nicht halten (37,31 €) | Im Minus liegt zur Stunde die Aktie von Qiagen NV . Der jüngste Kurs betrug 37,31 Euro. Für das Wertpapier von Qiagen NV steht gegenwärtig ein Verlust von 1,39 Prozent zu Buche. Die Aktie verbilligte... ► Artikel lesen | |
| EVOTEC | 8,105 | -0,98 % | Kurs von Evotec steigt etwas (8,85 €) | Die Evotec-Aktie notiert heute fester. Das Papier kostete zuletzt 8,85 Euro. Am Aktienmarkt liegt die Evotec-Aktie zur Stunde im Plus. Die Aktie legte um 33 Cent zu. Aktuell wird das Wertpapier an der... ► Artikel lesen | |
| ARCELLX | 64,91 | 0,00 % | Arcellx GAAP EPS of -$2.00 misses by $0.40, revenue of $107.94M | ||
| PRAXIS PRECISION MEDICINES | 38,540 | -40,74 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Update on Essential3 and Corporate Update | BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| BIONTECH | 107,50 | +0,66 % | Überflieger 2025: Valneva, BioNTech oder CureVac? | Biotech-Aktien von Valneva, BioNTech oder Curevac konnten nach langen Durstsrecken in den letzten Monaten wieder Momentum generieren und neue Anleger gewinnen. Allen voran der französische Impfstoffentwickler... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,430 | 0,00 % | ADMA Biologics Q4 2024 Earnings Preview | ||
| AVIDITY BIOSCIENCES | 30,750 | +5,71 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights | Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 31,300 | 0,00 % | Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus | ||
| GUBRA | 91,60 | +16,54 % | AKTIONÄR-Depotwert Gubra: Umsatzprognose übertroffen - Showdown im April | Der dänische Wirkstoffforscher Gubra kann auf ein hervorragendes Jahr 2024 zurückblicken. Vor allem das hochprofitable Forschungsdienstleistungsgeschäft (CRO-Business) konnte die ursprünglichen Erwartungen... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,330 | 0,00 % | Beam Therapeutics Inc. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Beam Therapeutics Inc. (BEAM):Earnings: -$90.35 million in Q4 vs. $142.80 million in the same period last year.
EPS: -$1.09 in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,700 | 0,00 % | Akeso, Inc.: Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs | HONG KONG, Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 23,670 | 0,00 % | JMP cuts Structure Therapeutics price target to $87 |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,050 (+7,09 %) liegt der Kurs bei 0,755 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.
